Prime Medicine clears NZ hurdle for first in vivo Prime Editing trial
Prime Medicine has received clearance from New Zealand's Medicines and Medical Devices Safety Authority (Medsafe) for its Clinical Trial Application covering PM577a, an investigational Prime Editing therapy for Wilson Disease (WD). The Cambridge, Massachusetts-based company says the clearance is the first clinical authorisation for any in vivo Prime Editing therapy it has developed, and enables the start of a global Phase 1/2 study expected to open in the second half of 2026.
PM577a is designed to correct the H1069Q point mutation in the ATP7B gene, which the company says accounts for approximately 30 to 50 per cent of WD-associated variants in the United States and Europe. The candidate is delivered as a lipid nanoparticle (LNP) formulation via a single intravenous infusion, targeting hepatocytes where the defective copper-transport protein is expressed.
The trial design
The Phase 1/2 study is an open-label, first-in-human, dose-escalation trial in adults and adolescents with WD who are clinically stable on current standard-of-care therapy. Endpoints include safety and tolerability alongside biological activity measures: copper efflux assessed by copper-64 PET imaging, serum ceruloplasmin, non-ceruloplasmin bound copper, 24-hour urinary copper excretion, and hepatic copper by biopsy. Chief Medical Officer Mohammed Asmal said the inclusion of 64Cu PET as a non-invasive functional readout of ATP7B activity is "a particular strength of the programme," with proof-of-concept data expected in 2027.
Wilson Disease affects an estimated one in 30,000 people globally and is caused by loss-of-function mutations in ATP7B, which impair the liver's ability to excrete copper via bile. Copper accumulates progressively, damaging the liver, brain, kidneys, and cornea. Current treatments, principally copper chelators and zinc salts, require lifelong daily dosing and carry meaningful tolerability and adherence burdens. Liver transplantation is the only established curative option but is constrained by organ availability.
Market context and competitive landscape
The broader field of in vivo gene editing for liver-directed rare diseases is increasingly competitive, with Intellia Therapeutics, Beam Therapeutics, and Verve Therapeutics each advancing LNP-delivered programmes targeting hepatic targets via CRISPR-based or base-editing approaches. Prime Editing is positioned by the company as more precise than base editing, capable of all twelve types of point-mutation correction without introducing double-strand DNA breaks. Whether that technical differentiation translates into a clinical advantage remains to be demonstrated in human data.
Prime Medicine has also signalled a modular expansion strategy for WD: a follow-on candidate targeting the R778L mutation, which is common in East Asian populations, is already in preclinical development using the same LNP delivery platform. The company says the shared platform architecture could allow relatively rapid iteration across additional ATP7B pathogenic variants, extending the addressable patient population considerably beyond the H1069Q cohort enrolled in the initial study.
New Zealand is a frequently chosen jurisdiction for first-in-human studies by North American biotechs, partly because Medsafe operates a straightforward CTA pathway and the regulatory timeline is often shorter than a US IND review. Clearance there does not pre-empt separate submissions to the FDA or EMA, and investors will be watching for IND or CTA approvals in larger markets as the company moves toward broader enrolment.